

CURRENT REPORT 6/2025

February 25, 2025

Disclosure of delayed inside information regarding the decision to commence the collective redundancy process in the Company and the commencement of the consultation procedure with representatives of the Company's employees

The Management Board of Ryvu Therapeutics S.A., with its registered office in Kraków, Poland ("**Issuer**", "**Company**") hereby discloses to the public inside information regarding the decision to commence the process of collective redundancy in the Company and the commencement of the consultation procedure on the intended collective redundancy with representatives of the Company's employees, the public disclosure of which was delayed on 4 February 2025.

At the same time, the Management Board of the Issuer informs that the process of the collective redundancy has been considered to be a protracted process, the result of which will be the determination of the rules of conduct in matters concerning employees affected by the intended collective redundancy. In the course of this process, the Issuer identified an intermediate stage that met the criteria for qualifying as inside information. Disclosure of the inside information regarding the occurrence of an intermediate stage in the collective redundancy process has been delayed until the completion of the consultation procedure with employee representatives and the adoption of the collective redundancy rules (which took place on February 24, 2025), as announced by the Issuer in current report No. 5/2025 of February 25, 2025).

Content of the delayed inside information:

*The Management Board of Ryvu Therapeutics S.A. with its registered office in Kraków (the "**Company**") hereby informs that on 4 February 2025 the resolution on the decision to commence the process of redundancy of employees pursuant to the Act of 13 March 2003 on special terms and conditions for terminating employment relationships with employees for reasons not related to the employees, i.e. collective redundancy of the Company's employees (the "**Collective Redundancy**") and to commence the procedure of consultation of the intended Collective Redundancy with employee representatives was adopted.*

The decision on carrying out of Collective Redundancy is based on: (i) the Company's failure to fully achieve its business objectives in 2023 and 2024, (ii) the limitation of cooperation with the Company's partner, BioNTech SE, with its registered office in Mainz, in the scope specified by the Company in current report No. 1/2025 dated January 29,

2025, and (iii) the inability to secure sufficient financial support to continue research activities at the previously planned scale.

The Collective Redundancy will be carried out after consultations with employee representatives.

The Collective Redundancy will be carried out by an estimated date of June 30, 2025 and will affect no more than 145 employees of the Company.

In the opinion of the Management Board, disclosure of information on the decision to commence the process of collective redundancy of the Company's employees and the commencement of the consultation procedure on the intended collective redundancy with employee representatives prior to the conclusion of consultations and prior to the determination of the rules of conduct in matters concerning the employees affected by the intended collective redundancy could adversely affect the course of consultations and the determination of the final rules of the collective redundancy, and thus lead to adverse effects for the Company in the area of employment, relations with employees, and even adverse financial consequences, as well as to affect the incorrect assessment of this information by the market. In addition, in the opinion of the Management Board, the delay in the disclosure of the inside information did not mislead the public, and the Company took steps to protect the confidentiality of the inside information.

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Article 17.4 of MAR

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice-President of the Management Board
-